Related references
Note: Only part of the references are listed.Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
RADIATION WITH OR WITHOUT 6 MONTHS OF ANDROGEN SUPPRESSION THERAPY IN INTERMEDIATE- AND HIGH-RISK CLINICALLY LOCALIZED PROSTATE CANCER: A POSTRANDOMIZATION ANALYSIS BY RISK GROUP
Paul L. Nguyen et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2010)
Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate Cancer
Nancy L. Keating et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden
Mieke Van Hemelrijck et al.
LANCET ONCOLOGY (2010)
Reimbursement Policy and Androgen-Deprivation Therapy for Prostate Cancer.
Vahakn B. Shahinian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Duration of Androgen Suppression in the Treatment of Prostate Cancer
Michel Bolla et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Prostate-Specific Antigen, Prostate Cancer, and Disorders of Hemostasis
Giuseppe Lippi et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2009)
Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the US medicare population
Christopher J. Weight et al.
CANCER (2008)
Cognitive effects of hormone therapy in men with prostate cancer
Christian J. Nelson et al.
CANCER (2008)
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610
Mack Roach et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients
Alok A. Khorana et al.
CANCER (2007)
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
Erik von Elm et al.
LANCET (2007)
Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer
Christopher S. Saigal et al.
CANCER (2007)
Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions
Anthony V. D'Amico et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate
Anthony V. D'Amico et al.
CANCER (2007)
Experimental arterial thrombosis regulated by androgen and its receptor via modulation of platelet activation
ShiJun Li et al.
THROMBOSIS RESEARCH (2007)
Intraoperative and early postoperative complications of radical retropubic prostatectomy
Virgilijus Klevecka et al.
UROLOGIA INTERNATIONALIS (2007)
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Nancy L. Keating et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Insulin sensitivity during combined androgen blockade for prostate cancer
MR Smith et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial
JW Denham et al.
LANCET ONCOLOGY (2005)
Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma
VB Shahinian et al.
CANCER (2005)
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer - A randomized controlled trial
AV D'Amico et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas
M Wahrenbrock et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy
LH Klotz et al.
JOURNAL OF UROLOGY (2003)
National practice patterns and time trends in androgen ablation for localized prostate cancer
MR Cooperberg et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer
M Han et al.
JOURNAL OF UROLOGY (2003)
Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02
GE Hanks et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy
A Berruti et al.
JOURNAL OF UROLOGY (2002)
Molecular basis for the relationship between thrombosis and cancer
FR Rickles et al.
THROMBOSIS RESEARCH (2001)
Development of a comorbidity index using physician claims data
CN Klabunde et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2000)
Effect of testosterone on the number of NADPH diaphorase-stained nerve fibers in the rat corpus cavernosum and dorsal nerve
K Baba et al.
UROLOGY (2000)
Risk factors for deep vein thrombosis and pulmonary embolism -: A population-based case-control study
JA Heit et al.
ARCHIVES OF INTERNAL MEDICINE (2000)
Share Paper
